GSK2878175 in Chronic Hepatitis C

Phase 1, randomised, single-blind trial of gsk2878175 in hepatitis C (HCV) (4 cohorts), sponsored by GSK. Primary endpoints: Safety as assessed by the collection of adverse events (AEs), Safety as assessed by hematology, clinical chemistry, urinalysis, vital signs, electrocardiogram (ECG) intervals, ECG rhythm telemetry, pulmonary function tests, respiratory rate and lung auscultation and 5 more. Started Dec 2013; status: completed.